Jacobs M R, Aronoff S C, Appelbaum P C, Yamabe S
Case Western Reserve University School of Medicine, Cleveland, OH 44106.
J Chemother. 1989 Jun;1(3):151-4. doi: 10.1080/1120009x.1989.11738883.
YTR 830, now known as tazobactam, is a new penicillanic acid sulfone beta-lactamase inhibitor. The in vitro activity of YTR 830 combined with various penicillins was determined and compared to that of clavulanate and sulbactam combined with the same agents. Combined with ampicillin or amoxicillin, all three inhibitors were active against beta-lactamase producing strains of Staphylococcus aureus, Haemophilus influenzae, Klebsiella, Citrobacter diversus, and all anaerobes except for Bacteroides fragilis homology group II. YTR 830 was also effective against Escherichia coli and indole-positive Proteus. The inhibitors had no effect against Enterobacter or Serratia. Overall, the activity of YTR 830 was comparable to that of clavulanate, and superior to that of sulbactam.
YTR 830，现称为他唑巴坦，是一种新型青霉烷砜β-内酰胺酶抑制剂。测定了YTR 830与各种青霉素联合使用时的体外活性，并与克拉维酸和舒巴坦与相同药物联合使用时的活性进行了比较。与氨苄西林或阿莫西林联合使用时，这三种抑制剂对产β-内酰胺酶的金黄色葡萄球菌、流感嗜血杆菌、克雷伯菌、奇异柠檬酸杆菌菌株以及除脆弱拟杆菌同源群II之外的所有厌氧菌均有活性。YTR 830对大肠杆菌和吲哚阳性变形杆菌也有效。这些抑制剂对肠杆菌或沙雷氏菌无效。总体而言，YTR 830的活性与克拉维酸相当，且优于舒巴坦。
